What is the interaction between propranolol (beta blocker) and duloxetine (serotonin-norepinephrine reuptake inhibitor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Propranolol and duloxetine can be used together, but their combination requires careful monitoring due to potential interactions, particularly the risk of additive effects on heart rate and blood pressure, as well as the potential for duloxetine to increase propranolol blood levels by inhibiting the CYP2D6 enzyme 1. When considering the interaction between propranolol and duloxetine, it's essential to understand the mechanisms of both drugs. Propranolol, a beta-blocker, affects heart rate and blood pressure, while duloxetine, an SNRI antidepressant, influences norepinephrine levels, which also impacts cardiovascular function.

Key Considerations

  • The combination may cause additive effects on blood pressure, with propranolol potentially enhancing duloxetine's blood pressure-increasing effects in some patients while counteracting them in others.
  • Duloxetine may increase propranolol blood levels by inhibiting the CYP2D6 enzyme that metabolizes propranolol, potentially intensifying its effects and side effects.
  • Patients taking both medications should monitor for symptoms like dizziness, lightheadedness, excessive fatigue, or unusual heart rate changes.
  • Blood pressure should be checked regularly, especially when starting the combination or changing doses.
  • Both medications can also independently cause drowsiness, so caution is advised when performing tasks requiring alertness.
  • Neither medication should be stopped abruptly as this could lead to withdrawal symptoms or rebound effects. Given the potential for significant interactions, careful patient monitoring and dose adjustments are necessary to minimize risks and ensure the best possible outcomes in terms of morbidity, mortality, and quality of life.

From the Research

Interaction between Propranolol and Duloxetine

  • The interaction between propranolol and duloxetine is a significant concern due to the potential for increased risk of hemodynamic adverse events, such as hypotension, bradycardia, and falls 2.
  • Duloxetine is a potent inhibitor of cytochrome P450 2D6 liver enzymes (CYP2D6) and can increase the plasma concentrations of certain β-blockers, including propranolol, when administered concomitantly 2.
  • A study found that patients receiving antidepressants with moderate to strong CYP2D6 inhibitory potential, including duloxetine, had a greater risk for hospitalization or emergency department visits for hemodynamic events than those initiated on antidepressants with weak CYP2D6 inhibition 2.
  • The concurrent use of propranolol and duloxetine may lead to increased morbidity, particularly in patients with advanced age, male sex, higher β-blocker doses, and African American race or Hispanic ethnicity 2.
  • Another study reported a case of successful concomitant clinical use of propranolol and an antidepressant drug, suggesting that the therapeutic effects of the antidepressant were not attenuated by the concurrent use of propranolol 3.
  • However, the study did not specifically investigate the interaction between propranolol and duloxetine, and more research is needed to fully understand the potential risks and benefits of this combination 3.

Orthostatic Hypotension

  • Orthostatic hypotension (OH) is a potential adverse effect of the combination of propranolol and duloxetine, particularly in older adults 4.
  • A study found that OH was not associated with a higher risk of cardiovascular disease events, but was associated with hypotension-related hospitalizations or emergency department visits and bradycardia 5.
  • The study suggested that symptomless OH during hypertension treatment should not be viewed as a reason to down-titrate therapy, even in the setting of a lower BP goal 5.
  • Another study reported that propranolol may be beneficial in patients with OH secondary to failure in peripheral vasoconstriction, but ineffective in patients with OH secondary to a fall in cardiac output 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.